Impact of an Interleukin-1 Receptor Antagonist and Erythropoietin on Experimental Myocardial Ischemia/Reperfusion Injury
Background. Revascularization of infarcted myocardium results in release of inflammatory cytokines mediating myocardial reperfusion injury and heart failure. Blockage of inflammatory pathways dampens myocardial injury and reduces infarct size. We compared the impact of the interleukin-1 receptor ant...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/2012/737585 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561047779672064 |
|---|---|
| author | Christina Grothusen Angelika Hagemann Tim Attmann Jan Braesen Ole Broch Jochen Cremer Jan Schoettler |
| author_facet | Christina Grothusen Angelika Hagemann Tim Attmann Jan Braesen Ole Broch Jochen Cremer Jan Schoettler |
| author_sort | Christina Grothusen |
| collection | DOAJ |
| description | Background. Revascularization of infarcted myocardium results in release of inflammatory cytokines mediating myocardial reperfusion injury and heart failure. Blockage of inflammatory pathways dampens myocardial injury and reduces infarct size. We compared the impact of the interleukin-1 receptor antagonist Anakinra and erythropoietin on myocardial ischemia/reperfusion injury. In contrast to others, we hypothesized that drug administration prior to reperfusion reduces myocardial damage. Methods and Results. 12–15 week-old Lewis rats were subjected to myocardial ischemia by a 1 hr occlusion of the left anterior descending coronary artery. After 15 min of ischemia, a single shot of Anakinra (2 mg/kg body weight (bw)) or erythropoietin (5000 IE/kg bw) was administered intravenously. In contrast to erythropoietin, Anakinra decreased infarct size (𝑃<0.05, 𝑁=4/group) and troponin T levels (𝑃<0.05, 𝑁=4/group). Conclusion. One-time intravenous administration of Anakinra prior to myocardial reperfusion reduces infarct size in experimental ischemia/reperfusion injury. Thus, Anakinra may represent a treatment option in myocardial infarction prior to revascularization. |
| format | Article |
| id | doaj-art-ddd641b54c844a0fbad5ab06c367b4b5 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-ddd641b54c844a0fbad5ab06c367b4b52025-02-03T01:26:09ZengWileyThe Scientific World Journal1537-744X2012-01-01201210.1100/2012/737585737585Impact of an Interleukin-1 Receptor Antagonist and Erythropoietin on Experimental Myocardial Ischemia/Reperfusion InjuryChristina Grothusen0Angelika Hagemann1Tim Attmann2Jan Braesen3Ole Broch4Jochen Cremer5Jan Schoettler6Department of Cardiovascular Surgery, University Medical Center of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, Haus 18, 24105 Kiel, GermanyDepartment of Cardiovascular Surgery, University Medical Center of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, Haus 18, 24105 Kiel, GermanyDepartment of Cardiovascular Surgery, University Medical Center of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, Haus 18, 24105 Kiel, GermanyDepartment of Pathology, University Medical Center of Schleswig-Holstein, 24105 Kiel, GermanyDepartment of Anaesthesiology and Intensive Care Medicine, University Medical Center of Schleswig-Holstein, 24105 Kiel, GermanyDepartment of Cardiovascular Surgery, University Medical Center of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, Haus 18, 24105 Kiel, GermanyDepartment of Cardiovascular Surgery, University Medical Center of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, Haus 18, 24105 Kiel, GermanyBackground. Revascularization of infarcted myocardium results in release of inflammatory cytokines mediating myocardial reperfusion injury and heart failure. Blockage of inflammatory pathways dampens myocardial injury and reduces infarct size. We compared the impact of the interleukin-1 receptor antagonist Anakinra and erythropoietin on myocardial ischemia/reperfusion injury. In contrast to others, we hypothesized that drug administration prior to reperfusion reduces myocardial damage. Methods and Results. 12–15 week-old Lewis rats were subjected to myocardial ischemia by a 1 hr occlusion of the left anterior descending coronary artery. After 15 min of ischemia, a single shot of Anakinra (2 mg/kg body weight (bw)) or erythropoietin (5000 IE/kg bw) was administered intravenously. In contrast to erythropoietin, Anakinra decreased infarct size (𝑃<0.05, 𝑁=4/group) and troponin T levels (𝑃<0.05, 𝑁=4/group). Conclusion. One-time intravenous administration of Anakinra prior to myocardial reperfusion reduces infarct size in experimental ischemia/reperfusion injury. Thus, Anakinra may represent a treatment option in myocardial infarction prior to revascularization.http://dx.doi.org/10.1100/2012/737585 |
| spellingShingle | Christina Grothusen Angelika Hagemann Tim Attmann Jan Braesen Ole Broch Jochen Cremer Jan Schoettler Impact of an Interleukin-1 Receptor Antagonist and Erythropoietin on Experimental Myocardial Ischemia/Reperfusion Injury The Scientific World Journal |
| title | Impact of an Interleukin-1 Receptor Antagonist and Erythropoietin on Experimental Myocardial Ischemia/Reperfusion Injury |
| title_full | Impact of an Interleukin-1 Receptor Antagonist and Erythropoietin on Experimental Myocardial Ischemia/Reperfusion Injury |
| title_fullStr | Impact of an Interleukin-1 Receptor Antagonist and Erythropoietin on Experimental Myocardial Ischemia/Reperfusion Injury |
| title_full_unstemmed | Impact of an Interleukin-1 Receptor Antagonist and Erythropoietin on Experimental Myocardial Ischemia/Reperfusion Injury |
| title_short | Impact of an Interleukin-1 Receptor Antagonist and Erythropoietin on Experimental Myocardial Ischemia/Reperfusion Injury |
| title_sort | impact of an interleukin 1 receptor antagonist and erythropoietin on experimental myocardial ischemia reperfusion injury |
| url | http://dx.doi.org/10.1100/2012/737585 |
| work_keys_str_mv | AT christinagrothusen impactofaninterleukin1receptorantagonistanderythropoietinonexperimentalmyocardialischemiareperfusioninjury AT angelikahagemann impactofaninterleukin1receptorantagonistanderythropoietinonexperimentalmyocardialischemiareperfusioninjury AT timattmann impactofaninterleukin1receptorantagonistanderythropoietinonexperimentalmyocardialischemiareperfusioninjury AT janbraesen impactofaninterleukin1receptorantagonistanderythropoietinonexperimentalmyocardialischemiareperfusioninjury AT olebroch impactofaninterleukin1receptorantagonistanderythropoietinonexperimentalmyocardialischemiareperfusioninjury AT jochencremer impactofaninterleukin1receptorantagonistanderythropoietinonexperimentalmyocardialischemiareperfusioninjury AT janschoettler impactofaninterleukin1receptorantagonistanderythropoietinonexperimentalmyocardialischemiareperfusioninjury |